Apnimed, Inc. Common Stock (NASDAQ:APMD) — Market Cap & Net Worth
Market Cap & Net Worth: Apnimed, Inc. Common Stock (APMD)
Apnimed, Inc. Common Stock (NASDAQ:APMD) has a market capitalization of $990.40 Million ($990.40 Million) as of August 24, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8980 globally and #2551 in its home market, demonstrating a -2.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apnimed, Inc. Common Stock's stock price $28.03 by its total outstanding shares 39823183 (39.82 Million). Check APMD stock price and chart for real-time trading data and today's change.
Apnimed, Inc. Common Stock Market Cap History: 2026 to 2026
Apnimed, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $1.12 Billion to $1.12 Billion (0.00% CAGR).
Apnimed, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apnimed, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check net assets of Apnimed, Inc. Common Stock to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of APMD by Market Capitalization
Companies near Apnimed, Inc. Common Stock in the global market cap rankings as of August 24, 2026. Also see Apnimed, Inc. Common Stock operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Key companies related to Apnimed, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #188 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #323 globally with a market cap of $83.19 Billion USD.
- CSL Ltd (AU:CSL): Ranked #475 globally with a market cap of $57.77 Billion USD ( AU$81.65 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #564 globally with a market cap of $48.66 Billion USD ( ₩71.80 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #188 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $548.05 |
| #323 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $83.19 Billion | $834.04 |
| #475 | CSL Ltd | AU:CSL | $57.77 Billion | AU$168.30 |
| #564 | Samsung Biologics Co Ltd | KO:207940 | $48.66 Billion | ₩1551000.00 |
Apnimed, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Apnimed, Inc. Common Stock's market cap moved from $1.12 Billion to $ 1.12 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 24th, 2026 the market cap of Apnimed, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $990.40 Million USD |
| MoneyControl | $990.40 Million USD |
| MarketWatch | $990.40 Million USD |
| marketcap.company | $990.40 Million USD |
| Reuters | $990.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apnimed, Inc. Common Stock
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Ca… Read more